Trial Profile
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2016
Price :
$35
*
At a glance
- Drugs BMS 986020 (Primary)
- Indications Systemic scleroderma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 14 Mar 2016 Status changed from not yet recruiting to withdrawn prior to enrolment, according to ClinicalTrials.gov record.
- 22 Jan 2016 Planned End Date changed from 1 Jul 2019 to 1 Oct 2019, according to ClinicalTrials.gov record.
- 22 Jan 2016 Planned primary completion date changed from 1 Jul 2019 to 1 Oct 2019, according to ClinicalTrials.gov record.